185 related articles for article (PubMed ID: 11773309)
1. Patient preferences for adjuvant chemotherapy of early breast cancer: how much benefit is needed?
Simes RJ; Coates AS
J Natl Cancer Inst Monogr; 2001; (30):146-52. PubMed ID: 11773309
[TBL] [Abstract][Full Text] [Related]
2. Patients' preferences for adjuvant chemotherapy in early breast cancer: what makes AC and CMF worthwhile now?
Duric VM; Stockler MR; Heritier S; Boyle F; Beith J; Sullivan A; Wilcken N; Coates AS; Simes RJ
Ann Oncol; 2005 Nov; 16(11):1786-94. PubMed ID: 16126738
[TBL] [Abstract][Full Text] [Related]
3. Psychosocial factors and patients' preferences for adjuvant chemotherapy in early breast cancer.
Duric VM; Butow PN; Sharpe L; Boyle F; Beith J; Wilcken NR; Heritier S; Coates AS; John Simes R; Stockler MR
Psychooncology; 2007 Jan; 16(1):48-59. PubMed ID: 16856128
[TBL] [Abstract][Full Text] [Related]
4. Survival benefit needed to undergo chemotherapy: Patient and physician preferences.
Vaz-Luis I; O'Neill A; Sepucha K; Miller KD; Baker E; Dang CT; Northfelt DW; Winer EP; Sledge GW; Schneider B; Partridge AH
Cancer; 2017 Aug; 123(15):2821-2828. PubMed ID: 28323331
[TBL] [Abstract][Full Text] [Related]
5. Adjuvant chemotherapy in early breast cancer.
Ejlertsen B
Dan Med J; 2016 May; 63(5):. PubMed ID: 27127018
[TBL] [Abstract][Full Text] [Related]
6. Comparing patients' and their partners' preferences for adjuvant chemotherapy in early breast cancer.
Duric VM; Butow PN; Sharpe L; Heritier S; Boyle F; Beith J; Wilcken NR; Coates AS; Simes RJ; Stockler MR
Patient Educ Couns; 2008 Aug; 72(2):239-45. PubMed ID: 18434070
[TBL] [Abstract][Full Text] [Related]
7. What survival benefits do premenopausal patients with early breast cancer need to make endocrine therapy worthwhile?
Thewes B; Meiser B; Duric VM; Stockler MR; Taylor A; Stuart-Harris R; Links M; Wilcken N; McLachlan SA; Phillips KA; Beith J; Boyle F; Friedlander ML
Lancet Oncol; 2005 Aug; 6(8):581-8. PubMed ID: 16054569
[TBL] [Abstract][Full Text] [Related]
8. Postoperative radiotherapy in high-risk premenopausal women with breast cancer who receive adjuvant chemotherapy. Danish Breast Cancer Cooperative Group 82b Trial.
Overgaard M; Hansen PS; Overgaard J; Rose C; Andersson M; Bach F; Kjaer M; Gadeberg CC; Mouridsen HT; Jensen MB; Zedeler K
N Engl J Med; 1997 Oct; 337(14):949-55. PubMed ID: 9395428
[TBL] [Abstract][Full Text] [Related]
9. Multi-agent chemotherapy for early breast cancer.
Early Breast Cancer Trialists' Collaborative Group
Cochrane Database Syst Rev; 2002; (1):CD000487. PubMed ID: 11869577
[TBL] [Abstract][Full Text] [Related]
10. Health-related quality of life in early breast cancer.
Groenvold M
Dan Med Bull; 2010 Sep; 57(9):B4184. PubMed ID: 20816024
[TBL] [Abstract][Full Text] [Related]
11. Patients' preferences for adjuvant chemotherapy in early breast cancer: a review of what makes it worthwhile.
Duric V; Stockler M
Lancet Oncol; 2001 Nov; 2(11):691-7. PubMed ID: 11902540
[TBL] [Abstract][Full Text] [Related]
12. Sequential methotrexate and fluorouracil for the treatment of node-negative breast cancer patients with estrogen receptor-negative tumors: eight-year results from National Surgical Adjuvant Breast and Bowel Project (NSABP) B-13 and first report of findings from NSABP B-19 comparing methotrexate and fluorouracil with conventional cyclophosphamide, methotrexate, and fluorouracil.
Fisher B; Dignam J; Mamounas EP; Costantino JP; Wickerham DL; Redmond C; Wolmark N; Dimitrov NV; Bowman DM; Glass AG; Atkins JN; Abramson N; Sutherland CM; Aron BS; Margolese RG
J Clin Oncol; 1996 Jul; 14(7):1982-92. PubMed ID: 8683228
[TBL] [Abstract][Full Text] [Related]
13. A quality-adjusted time without symptoms or toxicity (Q-TWiST) analysis of adjuvant radiation therapy and chemotherapy for resectable rectal cancer.
Gelber RD; Goldhirsch A; Cole BF; Wieand HS; Schroeder G; Krook JE
J Natl Cancer Inst; 1996 Aug; 88(15):1039-45. PubMed ID: 8683634
[TBL] [Abstract][Full Text] [Related]
14. Effect of Tailored Dose-Dense Chemotherapy vs Standard 3-Weekly Adjuvant Chemotherapy on Recurrence-Free Survival Among Women With High-Risk Early Breast Cancer: A Randomized Clinical Trial.
Foukakis T; von Minckwitz G; Bengtsson NO; Brandberg Y; Wallberg B; Fornander T; Mlineritsch B; Schmatloch S; Singer CF; Steger G; Egle D; Karlsson E; Carlsson L; Loibl S; Untch M; Hellström M; Johansson H; Anderson H; Malmström P; Gnant M; Greil R; Möbus V; Bergh J;
JAMA; 2016 Nov; 316(18):1888-1896. PubMed ID: 27825007
[TBL] [Abstract][Full Text] [Related]
15. Concurrent cyclophosphamide, methotrexate, and 5-fluorouracil chemotherapy and radiotherapy for breast carcinoma: a well tolerated adjuvant regimen.
Isaac N; Panzarella T; Lau A; Mayers C; Kirkbride P; Tannock IF; Vallis KA
Cancer; 2002 Aug; 95(4):696-703. PubMed ID: 12209711
[TBL] [Abstract][Full Text] [Related]
16. Adjuvant systemic therapy for women with node-positive breast cancer. The Steering Committee on Clinical Practice Guidelines for the Care and Treatment of Breast Cancer.
CMAJ; 1998 Feb; 158 Suppl 3():S52-64. PubMed ID: 9484279
[TBL] [Abstract][Full Text] [Related]
17. Burdens and benefits of adjuvant cyclophosphamide, methotrexate, and fluorouracil and tamoxifen for elderly patients with breast cancer: the International Breast Cancer Study Group Trial VII.
Crivellari D; Bonetti M; Castiglione-Gertsch M; Gelber RD; Rudenstam CM; Thürlimann B; Price KN; Coates AS; Hürny C; Bernhard J; Lindtner J; Collins J; Senn HJ; Cavalli F; Forbes J; Gudgeon A; Simoncini E; Cortes-Funes H; Veronesi A; Fey M; Goldhirsch A
J Clin Oncol; 2000 Apr; 18(7):1412-22. PubMed ID: 10735888
[TBL] [Abstract][Full Text] [Related]
18. Polychemotherapy for early breast cancer: an overview of the randomised trials. Early Breast Cancer Trialists' Collaborative Group.
Lancet; 1998 Sep; 352(9132):930-42. PubMed ID: 9752815
[TBL] [Abstract][Full Text] [Related]
19. Offering a choice between two adjuvant chemotherapy regimens: a pilot study to develop a decision aid for women with breast cancer.
Irwin E; Arnold A; Whelan TJ; Reyno LM; Cranton P
Patient Educ Couns; 1999 Jul; 37(3):283-91. PubMed ID: 14528554
[TBL] [Abstract][Full Text] [Related]
20. Epirubicin and cyclophosphamide, methotrexate, and fluorouracil as adjuvant therapy for early breast cancer.
Poole CJ; Earl HM; Hiller L; Dunn JA; Bathers S; Grieve RJ; Spooner DA; Agrawal RK; Fernando IN; Brunt AM; O'Reilly SM; Crawford SM; Rea DW; Simmonds P; Mansi JL; Stanley A; Harvey P; McAdam K; Foster L; Leonard RC; Twelves CJ;
N Engl J Med; 2006 Nov; 355(18):1851-62. PubMed ID: 17079759
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
